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Abstract 
Vitamin D has immuno-modulatory properties, and deficient levels of circulating 25-hydroxyvitamin D (<30 nmol/l) 
may contribute to increased risk of infectious illnesses. This narrative review summarises data on vitamin D status in 
Europe and updates results of randomised controlled trials (RCTs) regarding vitamin D and airway infections such as 
tuberculosis (TB) and acute upper respiratory tract infection. In Europe, the prevalence of vitamin D deficiency is up 
to 37 % in the general population and up to 80 % in nursing home residents and non-European immigrants. Half of 
TB patients have a migration background. While results of RCTs do not support the concept of beneficial adjunctive 
effects of vitamin D supplements in anti-TB treatment [odds ratio (OR) = 0.86; 95 % CI 0.62–1.19], the few published 
RCTs on the prophylaxis of TB suggest some protective vitamin D effects in individuals with deficient circulating 
25-hydroxyvitamin D levels. Regarding acute respiratory tract infection, RCTs indicate a significant risk reduction by 
vitamin D supplements [OR = 0.65; 95 % confidence interval (CI) 0.50–0.85]. There is evidence that daily administra-
tion is more effective than high-dose bolus administration [OR = 0.48 (95 % CI 0.30–0.77) vs. OR = 0.87 (95 % CI 
0.67–1.14)] and that individuals with deficient or insufficient (30–50 nmol/l) circulating 25-hydroxyvitamin D levels 
benefit most. Several vitamin D effects on innate immunity may explain these protective effects. In summary, there is 
possible evidence from RCTs for protective vitamin D effects on TB and likely evidence for protective effects on acute 
airway infection. Since vitamin D deficiency is prevalent in Europe, especially in institutionalised individuals and non-
European immigrants, daily oral vitamin D intake, e.g. 1000 international units, is an inexpensive measure to ensure 
adequate vitamin D status in individuals at risk.
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Background
Acute respiratory tract illnesses are very prevalent. 
Most people will develop an infection every year. The 
majority of these infections are caused by viruses, but 
suppurative and non-suppurative bacterial complica-
tions are also possible [1]. Common cold and influenza 
are frequent upper respiratory tract infections (URTIs) 
[2]. Pneumonia is a lower respiratory tract infection, 
which tends to be a far more serious condition than 
URTIs, such as common cold [3]. Airway infections are 
an important cause of disability, days lost from school or 
work, hospitalisation and mortality [4–6]. In temperate 
regions like Europe, there is strong seasonality of airway 
infections, with peak levels being observed in the win-
ter [7]. Tuberculosis (TB), caused by the intracellular 
pathogen M. tuberculosis (MTB), is an infection of the 
lower respiratory tract. In approximately 80 % of cases, 
TB affects the lung, and in 20 %, it affects any extrapul-
monary organ of the body including the skin. In Europe, 
tuberculosis was widespread in the 19th and early 20th 
centuries and was associated with high mortality rates 
[8]. TB is still among the worldwide number one killers 
among infectious diseases caused by single pathogens, 
with more than 9  m new cases and more than 1.5  m 
deaths per year [9].
It has been assumed that vitamin D status may influ-
ence infectious diseases like TB and acute URTI (see 
below). This assumption is based on findings that vita-
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below). This narrative review provides data on vitamin 
D status in Europe, the history of TB treatment by vita-
min D in Europe, and updates results of randomised con-
trolled trials (RCTs) on vitamin D and airway infections 
such as TB and acute URTI.
Vitamin D metabolism and status classification
Vitamin D has a special position among the vitamins 
because the human body is able to synthesise it from 
the precursor molecule 7-dehydrocholesterol (Fig.  1). 
This is generated by the skin upon sufficient exposure 
to solar ultraviolet radiation in wavelengths from 290 to 
315 nm (UVB radiation). Measurable quantities of vita-
min D also occur in some natural foods, in particular in 
oily fish like eel, salmon and herring, as well as in cod 
liver oil. Since its final effector molecule is produced in 
the human organism, some authors consider vitamin 
D more a pro-hormone than a vitamin sensu stricto 
[10]. With modern lifestyles, however, the majority of 
human beings worldwide stay indoors for most of the 
time. This certainly leads to diminished or even absent 
synthesis of vitamin D in the skin, in particular in certain 
risk groups including office workers, nursing home resi-
dents, coloured populations living in northern latitudes 
and women wearing traditional dresses which cover the 
whole body. Due to increasing numbers of people fall-
ing into one of the aforementioned risk groups, it is very 
likely that in future the vitamin nature of this essential 
substance will become the focus of interest, i.e. the need 
for its oral intake.
Vitamin D status is best determined by measuring 
circulating 25-hydroxyvitamin D (25OHD) in plasma 
or serum. 25OHD is the first hydroxylation product 
of vitamin D and is synthesised in the liver. The North 
American Institute of Medicine (IOM) has classified 
serum 25OHD levels of 50 to 125  nmol/l [20 to 50  ng/
ml] as sufficient [1  nmol/l =  0.4  ng/ml], levels between 
30 and 49.99 [12 and 19.99 ng/ml] as inadequate, levels 
below 30 nmol/l [12 ng/ml] as deficient and levels above 
125  nmol/l [50  ng/ml] as potentially harmful [11]. The 
‘deficient’ and ‘inadequate’ categories have been set up 
exclusively based on the effects of vitamin D on bone 
health. The assumption of potentially harmful vitamin D 
effects at levels above 125 nmol/L originates from results 
of prospective cohort studies of tumour incidence, myo-
cardial infarction and total mortality [11]. The Endocrine 
Society (ES), in contrast, has set the lower threshold of 
adequate 25OHD concentrations to 75  nmol/l (30  ng/
ml), i.e. 50 % higher than the IOM [12]. The ES-recom-
mendation is not only based on convincing evidence of 
positive vitamin D effects on the musculoskeletal system 
but also on potential evidence of positive extra-skeletal 
effects. The ES did not, however, define an upper thresh-
old of 25OHD levels.
The metabolically active form is 1,25-dihydroxyvitamin 
D (1,25[OH]2D), which is produced from 25OHD mainly 
in the kidney but also in different extra-renal tissues. The 
human organism usually regulates serum concentration 
of 1,25(OH)2D between quite strict limits. Therefore, 
1,25(OH)2D levels are clinically less meaningful. How-
ever, once the vitamin D supply becomes severely defi-
cient, the circulating 1,25(OH)2D level becomes substrate 
dependent, i.e. dependent on circulating 25OHD levels, 
and secondarily decreases as well [13].
To guarantee adequate vitamin D intake, the IOM rec-
ommends daily vitamin D intakes of 400, 600 and 800 
international units (1 IU = 0.025 µg) in the first year of 
life, following infancy up to 70 years of age, and beyond 
70 years of age, respectively. This corresponds well with 
the recommendations of the German, Austrian and 
Swiss Nutrition Society (D-A-CH) [11, 14]. IOM and 
European Food Safety Authority have set 4000  IU as 
the maximum permissible dose of safe daily vitamin D 
intake.
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Fig. 1 Simplified schematic vitamin D metabolism. Dietary vitamin D 
and endogenously produced vitamin D are both first metabolised in 
the liver into 25-hydroxyvitamin D and then in the kidney and various 
extra-renal tissues into the vitamin D hormone  
1,25-dihydroxyvitamin D
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Literature review strategy and methods
We performed a systematic literature search in Pub-
Med and Google Scholar without language restrictions 
for relevant publications released until June 30th, 2015, 
using the following terms: (“vitamin D” or “cholecalcif-
erol” or “25-hydroxyvitamin D”) and (“immune system” 
or “infection” or “infectious disorder” “infectious disease” 
or “immune defence” or “influenza” or “upper respira-
tory tract infection” or “tuberculosis” or “airway infec-
tion”). Personal collections of articles on this topic as 
well as references from selected articles were also used 
to extend the search. Some articles are not cited due to 
space limitations. We systematically analysed retrieved 
RCTs on vitamin D and tuberculosis/airway infection in 
an approach similar to meta-analyses. We used RevMan 
(Review Manager. Version 5.3.: The Nordic Cochrane 
Centre. The Cochrane Collaboration. Copenhagen, 2014) 
to perform the analyses.
Epidemiology of vitamin D deficiency in Europe
Circulating 25OHD levels can vary widely according to 
lifestyles, skin pigmentation, dietary vitamin D intake, 
season, latitude and health status. In the general adult 
population of selected European countries (Austria, 
Germany, United Kingdom, Denmark, Finland, Ireland 
and Poland), the prevalence of vitamin D deficiency, e.g. 
25OHD levels <25 nmol/l, is 11.6–37 % [15]. Moreover, 
the HELENA (healthy lifestyle in Europe by nutrition in 
adolescence) study has demonstrated that 15 % of Euro-
pean adolescents have 25OHD levels  <27.5 nmol/l [16]. 
This figure is similar to results of a representative Ger-
man survey in children and adolescents, where approxi-
mately 16 % had 25OHD levels <25 nmol/l [17]. Usually, 
peak levels of circulating 25OHD are achieved in sum-
mer, whereas a nadir is observed at the end of the winter. 
Results from a recent retrospective survey with 98,000 
patients tested between 2008 and 2011 in Northern 
Germany support the season dependency of vitamin D 
deficiency. Less than 10  % and near to 40  % of partici-
pants had vitamin D deficiency during the summer and 
the winter seasons, respectively [18]. In a nationwide 
cohort of British adults at age 45 years, the prevalence of 
25OHD levels <25 nmol/l was 3.2 % in summer/autumn 
and 15.5 % in winter/spring [19]. That study also demon-
strated latitudinal differences in 25OHD levels, with 8 % 
higher prevalence of deficient 25OHD levels in Scotland 
compared with the south of England. Data are in general 
agreement with a French study reporting in middle-aged 
men and women with a mean 25OHD level of 43 nmol/l 
in Northern France and 94  nmol/l in the southwest of 
France [20]. A particular risk group for vitamin D defi-
ciency is non-European immigrants. The aforementioned 
German survey reported deficient 25OHD levels in up 
to 30  % of migrant girls, compared with 17  % of native 
German girls [17]. In the Netherlands and Denmark, 
serum 25OHD was below 25 nmol/l in up to 80 % of non-
European immigrants, with particularly high prevalence 
in girls and women [15]. Another particular risk group 
for vitamin D deficiency is frail elderly people. In recent 
studies from Germany and Austria [21, 22], the supply 
situation was particularly poor in rehabilitation patients 
and nursing home residents. 67 and 75  % had vitamin 
D deficiency, respectively. In view of these devastating 
vitamin D deficiency statistics, it should be taken into 
consideration that the automated immunoassays meas-
uring 25OHD levels in blood may markedly vary, with 
significant impact on vitamin D status classification [23]. 
In November 2010, an international collaborative ini-
tiative organised by the office of dietary supplements of 
the National Institutes of Health therefore established 
a vitamin D standardisation program (VDSP) [24]. A 
recent study applied VDSP protocols to serum data from 
representative childhood/teenage and adult/older adult 
European populations [25]. An overall pooled estimate, 
irrespective of age, showed that 13 % of the 55,844 Euro-
pean individuals had yearly mean standardised serum 
25OHD levels <30 nmol/l. In Finnish and British immi-
grant groups, the prevalence was between 28 and 50 %.
History of treatment of airway infection
Cod liver oil and UVB radiation, which today are known 
to be the most effective sources of vitamin D for humans, 
have long been used to treat airway infections such as 
tuberculosis in Western Europe [26, 27]. In 1848, in one 
of the very first clinical trials on the treatment of TB, 
more than 1000 TB patients were either assigned to the 
verum group and received cod liver oil three times daily, 
or to the control group with simple nursing care. 33 % of 
the control group versus 19 % of the verum group expe-
rienced significant worsening of their disease or died 
[26]. In 1903, Niels Finsen was awarded the Nobel Prize 
in Physiology or Medicine for the proof that photother-
apy can cure lupus vulgaris (skin tuberculosis) [28]. In 
the absence of effective antibiotics and chemotherapy, 
heliotherapy (helios = sun) was quite popular in Western 
Europe, exposing TB patients to UV rich sunlight in high 
altitudes [27]. After the discovery of synthetic antitu-
berculous substances, starting with streptomycin in the 
1940s, heliotherapy was displaced by the more effective 
antituberculous chemotherapy [29]. In 2006, however, a 
German-American working group demonstrated that 
increased expression of the vitamin D receptor and of 
the 1α-hydroxylase gene (the 1α-hydroxylase synthesises 
25OHD) induces synthesis of the antimicrobial peptide 
cathelicidin in human macrophages [30]. In the same 
year, Cannell et  al. [31] put forward the hypothesis that 
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vitamin D deficiency increases the risk of contracting 
influenza in winter. Of note, during recent years, several 
other natural products such as bacterial lysates or com-
ponents of bacterial cells (ribosomal extracts), prebiotic 
oligosaccharides, probiotics and yeast-derived beta-glu-
cans have also been successfully used in airway infection 
prevention [32–35].
Clinical associations of vitamin D with tuberculosis
Two effects have so far assigned to vitamin D with 
regards to TB: (i) a potentially protective value of suf-
ficient vitamin D levels against reactivation of TB 
infections and (ii) the therapeutic effect of vitamin D 
supplementation on the clinical outcome of the active 
disease. With respect to preventive vitamin D effects, it 
is noteworthy that in European countries, approximately 
half of TB patients have a migration background. Glob-
ally, the prevalence of TB per 100,000 people is highest 
in sub-Saharan Africa and is also relatively high in Asia. 
It has been argued that immigrants become infected in 
their countries of origin and that the infection reacti-
vates upon enhanced vitamin D deficiency due to weaker 
sunlight in the Northern regions [36]. So far, two RCTs 
[37, 38] have investigated the protective effect of vita-
min D on TB. One trial [37] daily supplemented a verum 
group of school children in the high TB incidence setting 
of Mongolia with 800  IU and compared the additional 
numbers of latent TB infections measured with a tuber-
culin skin test with a placebo control group. The authors 
found a strong protective trend in the verum group (risk 
ratio: 0.41; 95 CI 0.16–1.09). Unfortunately, they did 
not provide baseline data on smear-positive pulmonary 
TB. The other trial [38] investigated the effect of a sin-
gle dose of 100,000  IU vitamin D on adult persons who 
had contact to TB index cases in the United Kingdom 
(UK). The authors could not see a protective effect on the 
risk of acquiring a latent TB infection as measured using 
ESAT-6/CFP-10-based interferon-gamma release assays. 
The authors observed, however, an enhanced antimicro-
bial in vitro activity of blood from verum group patients 
compared to controls against bacteria of a BCG vaccine 
strain. But the clinical relevance of this finding could not 
yet be established. Notably, in the Mongolian study, ini-
tial 25OHD levels were on average below 18 nmol/l, and 
thus in the range, the IOM has classified as deficient. In 
the UK study, mean initial 25OHD levels were 35 nmol/l 
and thus slightly above the deficiency range.
Table  1 lists six published RCTs [39–44] which have 
examined the therapeutic effect of vitamin D on the 
course of the disease. Four studies, one study and one 
study were conducted in Asia, Africa, and the UK, 
respectively. Different forms of pulmonary and extrapul-
monary TB were included in the studies. In five of the six 
trials, high bolus doses of vitamin D were administered 
once, on a weekly or on a monthly basis. One study only 
had daily supplemented vitamin D at a dose of 10,000 IU. 
In two studies, 25OHD levels were not measured, and in 
three other studies, initial 25OHD levels were on aver-
age already above 50 nmol/l. Results of individual studies 
and summary results are illustrated as odds ratios (ORs) 
and 95 % confidence intervals (CI) in Fig. 2. Cases which 
did not terminate the treatment according to the respec-
tive study protocols had to be excluded. Since there was 
no evidence of heterogeneity in study results (I2 = 23 %; 
P =  0.26), we used a fixed effects model. Overall, there 
was a non-significant reduction of TB infections in the 
vitamin D group (odds ratio: 0.86; 95  % CI 0.62–1.19; 
P = 0.338). Although in the study by Martineau [41] vita-
min D did not significantly affect time to sputum culture 
conversion in the whole study population, it did signifi-
cantly hasten sputum culture conversion in participants 
with the tt genotype of the TaqI vitamin D receptor poly-
morphism, indicating that vitamin D availability in target 
cells may indeed influence disease outcome. The studies 
were not designed to answer the question of whether 
vitamin D was able to reduce mortality in TB patients. 
Results would have been of scientific interest since ear-
lier systematic reviews and meta-analyses of RCTs had 
already demonstrated that vitamin D supplements reduce 
mortality from a variety of diseases [45, 46]. Interest-
ingly enough, several studies have also associated vitamin 
D deficiency with other forms of lower respiratory tract 
infections [47–50].
Clinical associations of vitamin D with acute airway 
infections
Studies of the influence of vitamin D on URTIs are 
methodically difficult because the duration and extent of 
the infections are not always easy to record objectively. 
Against this background, a Finnish study [51] stands out: 
absence from duty due to respiratory tract infections was 
studied in 800 recruits, i.e. a homogeneous group of fun-
damentally healthy young men. It showed that recruits 
with 25OHD concentrations of  <40  nmol/l (16  ng/ml) 
were unfit for work significantly more frequently than 
recruits with higher 25OHD. Based on these data, a ran-
domised controlled extension trial, in which the recruits 
received either 400 IU of vitamin D or a placebo, was con-
ducted over the winter season (October to March) [52]. 
The mean duration of days of absence from duty tended 
to be lower in the vitamin D group than in the placebo 
group (on average 2.2 vs. 3.0 days). Furthermore, the per-
centage of recruits with absence was significantly lower 
than in the placebo group (35.7 vs. 51.3 %). A meta-anal-
ysis of RCTs published by Bergman et al. [53] in 2013 sys-
tematically analysed the influence of vitamin D intake on 
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the risk of respiratory tract infection [53]. Included stud-
ies [52, 54–63] are listed in Table 2. Since publication of 
this meta-analysis [53], several other RCTs [64–68] have 
been published on this topic and are presented in Table 2, 
resulting in 16 studies in total. Of these 16 studies, 11 
were conducted in healthy subjects and five in patients, 
the study participants being children in six studies and 
adults in eleven studies. All 16 studies were included in 
a new systematic analysis using a random effect model 
(Fig. 3). Outcome was the number of patients experienc-
ing at least one episode of infection. Overall, vitamin D 
administration reduced the risk of infection significantly 
(odds ratio = 0.65; 95 % CI 0.50–0.85; P = 0.005). Exclu-
sion of the two studies by Manaseki-Holland et  al. [56, 
62] that used vitamin D to protect against a (repeat) epi-
sode of pneumonia did not change results substantially 
(odds ratio = 0.61; 95 % CI 0.44–0.84; P < 0.001). How-
ever, results showed significant heterogeneity among 
studies (I2 =  74  %, P  <  0.001), supporting the need for 
a random effects model. Subgroup analysis indicated 
that daily vitamin D administration was associated with 
a better outcome than (high-dose) bolus vitamin D 
administration [odds ratio  =  0.48 (95  % CI 0.30–0.77) 
vs. odds ratio  =  0.87 (95  % CI 0.67–1.14)]. Moreover, 
in three trials with initial 25OHD levels <50 nmol/l [54, 
60, 68], the odds ratio of vitamin D effectiveness was 
0.55 (95  % CI 0.20–1.55), indicating that initial 25OHD 
level may also influence vitamin D effectiveness. Nota-
bly, Simpson et  al. [67] reported that a protective vita-
min D effect could only be observed in the subgroup 
of individuals with initial 25OHD levels  <40  nmol/l. In 
these individuals, vitamin D resulted in a 44 % reduction 
in infection risk (P = 0.007). URTI and non-URTI were 
included in this analysis. In the study by Rees et al. [64], 
a further observational analysis of their data suggested 
a significant decreased rate ratio of 0.91 (95 % CI 0.83–
0.99) for URTI per 25 nmol/l increase in 25OHD. A few 
years ago, the analysis of an extensive US data set [69] 
revealed, as expected, that URTI shows strong seasonal 
variation, with the frequency peaking in winter. However, 
people with deficient circulating 25OHD (<25  nmo/l 
or <10 ng/ml) always exhibited a higher risk than people 
with adequate circulating 25OHD (>75 nmol/l or >30 ng/
ml). 
Table 1 Randomised, controlled trials of vitamin D for treatment of active tuberculosis
25OHD 25-hydroxyvitamin D; IU international units; ND not determined










Mean vitamin D 
dose (IU)
Duration Endpoint
Vit D Placebo Vit D Placebo
Nursyam [39] 2006 67 31 ND ND ND ND 10,000 daily 6 weeks Sputum conversion
Wejse [40] 2009 365 37 77 79 98 95 100,000 quarterly 12 months Sputum conversion
Martineau [41] 2011 146 31 21 21 101 23 4 × 100,000 6 days Sputum conversion
Salahuddin [42] 2013 259 28 52 58 220 50 2 × 600,000 12 weeks Sputum conversion
Ralph [43] 2013 200 28 ND ND ND ND 50,000 monthly 8 weeks Sputum conversion
Daley [44] 2015 247 43 58 54 72 60 100,000 quarterly 12 months Sputum conversion
Fig. 2 Meta-analysis of the efficacy of vitamin D therapy against tuberculosis. Results are presented as odds ratios. Error bars indicate 95 % confi-
dence intervals
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The results on acute respiratory tract infection are par-
ticularly interesting for two reasons: firstly, the data prove 
that vitamin D, in addition to its effects on the muscu-
loskeletal system, also possesses other important func-
tions of clinical relevance. Secondly, the data show that 
attention must be paid to the vitamin D supply not only 
during infancy and old age but also in otherwise healthy 
children and adults. Notably, the winter nadir in vitamin 
D status parallels the winter peak in airway infections.
As viral infections of the respiratory tract often pre-
cede bacterial infections, the results of a post hoc analy-
sis of the RECORD trial [70], a prospective randomised 
study with 5300 participants who received either 800 IU 
of vitamin D or a placebo daily for two to 5  years, are 
interesting: in the vitamin D group, there was a ten-
dency towards fewer self-reported infections (of any 
cause) and antibiotics use. Results are in line with data by 
Bergman et  al. on respiratory tract infection [59], dem-
onstrating a 63.5  % reduction in the taking of antibiot-
ics in the vitamin D group. In another post hoc analysis 
of a vitamin D study, an age-related effect of vitamin D 
on antibiotic intake was observed [71]: while vitamin D 
supplements did not reduce antibiotic intake in people 
under 70 years of age, patients aged 70 years and older in 
the control group required considerably more antibiotics 
than those in the vitamin D group. Although the results 
of the aforementioned three studies are provisional, and 
further studies on reduction of the need for antibiotics 
due to vitamin D are necessary, they provide promising 
evidence of a role of protective vitamin D effects on res-
piratory tract infections. Altogether, likely evidence exists 
that a sufficient vitamin D supply can prevent URTI.
Molecular effects of vitamin D on the immune 
system
Molecular vitamin D effects on the immune system may 
explain the protective clinical associations observed 
(Table  3). Since the 1980s, it has become increasingly 
clear that vitamin D plays a prominent role in innate 
immunity. Vitamin D receptors are found on mono-
cytes. These cells differentiate into macrophages under 
the influence of 1,25(OH)2D [72]. Macrophages express 
their own 1α-hydroxylase isoenzyme which intracellu-
larly synthesises the active 1,25(OH)2D. The activity of 
Table 2 Randomised, controlled trials of vitamin D for prevention of respiratory tract infections
25OHD 25-hydroxyvitamin D; IU international units; ND not determined; URTI upper respiratory tract infection; RTI respiratory tract infection
a significantly higher than placebo
b significantly lower than vitamin D group
c several studies were included. The vitamin D doses in the individual studies were as follows: 2000, 2800 and 6800 IU/daily, 20,000 and 40,000 IU/weekly and 100,000/
monthly, every 2 months or every 3 months
d  initial dose: 200,000 IU














Vit D Placebo Vit D Placebo
Aloia [54] 2007 208 60.6 46.9 43 86.9 43 800/2000 daily 3 years Influenza
Li-Ng [55] 2009 148 58.7 58.7 63 88.5 60.9 2000 daily 3 months URTI
Laaksi [52] 2010 164 Young men 78.7 74.4 72 51 400 daily 6 months Acute RTI
Manaseki-Holland 
[56]
2010 453 1.2 ND ND ND ND 100,000 (single dose) 3 weeks Pneumonia
Urashima [57] 2010 334 10.2 ND ND ND ND 1200 daily 4 months Influenza A
Majak [58] 2011 48 11.5 64.3 88 94 80 500 daily 6 months Acute RTI
Bergman [59] 2012 124 53.1 51.5 46.9 117.4 44 4000 daily 12 months RTI
Camargo [60] 2012 244 19.9 17.5 17 47.3 18 300 daily 7 weeks Acute RTI
Jorde [61] 2012 569 63 ND ND ND ND 3344c 12 months Influenza-like
Manaseki-Holland 
[62]
2012 3046 0.8 ND ND a b 100,000 quarterly 18 months Pneumonia
Murdoch [63] 2012 322 47.5 75.5 70 122.5 55 100,000 monthlyd 18 months URTI
Rees [64] 2013 759 58.1 62 63.1 ND ND 1000 daily 3–5 years URTI
Urashima [65] 2014 247 Students ND ND ND ND 2000 daily 2 months Influenza A
Goodall [66] 2014 471 19 ND ND ND ND 10,000 weekly 2 months URTI
Simpson [67] 2015 34 Healthy adults 60.5 76.4 107 46 20,000 weekly 17 weeks RTI
Martineau [68] 2015 250 47.9 49.8 49.4 69.4 46.5 120,000 bimonthly 1 year Acute RTI
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this enzyme is increased in activated macrophages [73]. 
During phagocytosis, macrophages incorporate patho-
gens such as MTB in the so-called phagosomes. Human 
macrophages which are infected with MTB show higher 
expression of the intracellular vitamin D receptor and of 
the 1α-hydroxylase in human macrophages than native 
macrophages [30]. 1,25(OH)2D directly and indirectly 
regulates the expression of cathelicidin and defensins, 
respectively [28, 30]. Cathelicidin induces the fusion 
of inactive phagosomes with active autophagosomes 
[74]. Under the further influence of cathelicidin, the 
autophagosomes can fuse with lysosomes to the autol-
ysosome [75]. As the next weapon of innate immunity, 
1,25(OH)2D induces the expression of lysosomal enzymes 
and of reactive oxygen species like nitric oxide, ultimately 
leading to increased antimicrobial activity [75]. The com-
bination of antimicrobial peptides and oxygen species 
may destroy intracellular viruses, fungi, and bacteria in 
the autolysosomes. Due to cathelicidin’s antiviral effects, 
it supports host defence against influenza virus or human 
immunodeficiency virus [76]. Notably, monocytic cathel-
icidin production is reduced in individuals with insuffi-
cient 25OHD or low 1,25(OH)2D levels [77].
The vitamin D innate host response is also active in 
many other cells like keratinocytes, gastrointestinal/
bronchial epithelial cells, decidual cells, trophoblas-
tic cells and natural killer cells [76, 78]. Accordingly, 
vitamin D bacterial action is broad-reaching and can 
provide protection against various pathogens, especially 
in airway infections [76]. By inducing the expression of 
defensins, vitamin D seems indirectly to help blocking 
of the membrane fusion mediated by viral hemaggluti-
nin, which might partly explain the antiviral potential 
that is ascribed to vitamin D, particularly with regard to 
influenza [57]. Finally, vitamin D plays a role in acquired 
immunity directly by acting on T cells and indirectly 
by regulating dendritic cells [76]. Vitamin D-mediated 
induction of immunoglobulin E expression together with 
eosinophil granulocytes supports the elimination of some 
extracellular pathogens like parasites or fungi [79]. Vita-
min D also restricts Th1/Th17 cell differentiation and 
favours Th2 differentiation [76]. High vitamin D levels 
seem to be concomitant with decreased pro-inflamma-
tory cytokines, which might have a positive effect on 
disease progression [57, 80]. Conversely, a low vitamin 
D status is associated with an activation of inflammatory 
processes [81]. Since it takes approximately 48 h between 
antigen recognition and full T cell activation, it has been 
speculated that if the innate immune system is able to 
clear the infection rapidly, the vitamin D-mediated delay 
of full T cell activation puts the brakes on excessive T cell 
proliferation to avoid immunopathology [76].
Conclusion
Vitamin D is an essential substance for the human body, 
but large population-based studies demonstrate that 
Fig. 3 Meta-analysis of the efficacy of vitamin D therapy against acute airway infections. Results are presented as odds ratios. Error bars indicate 
95 % confidence intervals
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vitamin D deficiency is widespread in Europe. Institu-
tionalised individuals and non-European immigrants 
are most affected. Moreover, the proportion of the lat-
ter group in European TB cases is high. Therefore, non-
European immigrants would probably benefit from 
improving their vitamin D status. Present data indicate 
that vitamin D deficiency increases the risk of acute air-
way infection. Of note, there is also evidence that vita-
min D can lower the risk of other common infections like 
sepsis, human immunodeficiency virus and hepatitis C 
virus [76, 82–86]. Due to the available evidence, the high 
prevalence of deficient vitamin D status in the general 
European population, and taking into consideration the 
benefit/risk ratio, vitamin D supplementation can there-
fore be considered for infection prophylaxis. Oral vita-
min D needs are increased, particularly in winter, due 
to the lower solar UVB radiation at this time of the year. 
Recommended oral vitamin D intakes of different nutri-
tion, osteoporosis and endocrine societies vary between 
600 and 2000  IU daily [10, 11, 14, 87, 88]. However, so 
far, recommendations have primarily been based on mus-
culoskeletal health and mortality. Regardless of whether 
airway infection is considered, there is general agree-
ment that the lower target circulating 25OHD should be 
50  nmol/l. From a recently published systematic review 
of RCTs, it can be concluded that, in the majority of peo-
ple, daily intake of 1000  IU should result in circulating 
25OHD levels >50 nmol/l [89]. Thus, it is reasonable and 
safe to take approximately 1000 IU of vitamin D daily to 
optimise non-specific immunity and prevent infection. 
When doing so, it is important to start supplementation 
in early autumn in order to ensure an adequate vitamin D 
level in winter. Supplementation should also take place all 
year round in people with an increased risk of vitamin D 
deficiency like office workers, non-European immigrants 
and frail elderly people. Vitamin D supplements are inex-
pensive (approx. 6,−€/100 tablets  =  22,−€/year) and 
have the advantage that they target not only the immune 
system but also other tissues like the musculoskeletal 
system.
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